Transforming cell therapy, one cell at a time
Challenges of traditional treatments
An allogeneic stem cell transplant has been the best hope for many patients fighting serious illnesses, such as blood cancers, since the procedure was first performed more than 50 years ago.
Our investigational cell therapies are designed to replace a patient's cancerous blood and immune system with a healthy one, with the goal of improving survival rates and quality of life for survivors.
Key complication of traditional treatments
Graft-versus-host disease (GvHD)
While an allogeneic stem cell transplant can have life-saving benefits for some patients, for others the transplant itself can prove fatal or lead to serious and long-lasting side effects, such as GvHD.
- GvHD is often a chronic, unpredictable condition that can strike at any time, upending the lives of patients long after they've received a traditional transplant
- For many patients, chronic GvHD remains a painful reminder of the cancer they defeated and prevents them from living the healthy life they had before their diagnosis
Source: Leukemia & Lymphoma Society (LLS). Graft-Versus-Host Disease. Published August 2021. FS32.
At Orca Bio, we don't accept these limitations, and we believe patients shouldn't have to either
Building a designer immune system
For illustrative purposes only. Not to scale.
Through cell selection, we develop high-precision cell therapies that can build a new, healthy blood and immune system for patients. This may significantly improve their chance of relapse-free survival while potentially lowering the risk of developing GvHD compared with traditional allogeneic transplant.
Our team handles this precious material with the utmost care because we know every cell therapy delivered could save a patient's life.